Novartis to launch Adamis' EpiPen rival in U.S. next year

‘)),R++>=w&&clearInterval(k)},250);if(!e.uabp343Flags.welect.enabled||UABPWelect()){if(uabp343Flags.protectStyles){var E=uabp343Flags.bait,B=uabp343Flags.maxBait||10,S=uabp343Flags.ignoreBaitProps,A=function(){var e=P(“style”);e.type=”text/css”;var t=!1,n=P(“style”);n.type=”text/css”;var a=!1;return function(r,i){if(i)if(“b”!==r||t)”r”===r&&(a?n.sheet.insertRule(i,0):(a=!0,F(n,i),document.body.appendChild(n)));else{if(t=!0,S)for(var o=0;oB){for(var j=0,I=[0],O=[E[0]],L=1;L-1;)j=n.floor(n.random()*E.length);I.push(j),O[L]=E[j]}E=O,uabp343Flags.bait=O}for(var T={},z=0;z-1){var r=a(“.mainSlideshow #div_gpt_mpu”,””);if(r){var i=P(“div”);n.MRTopPictureWrapper=i,t.MRTopPictureWrapper=i,H(i,”rsAHFs “),m([{selector:”#div_gpt_mpu”,cssApply:{display:”none”}}],i),_(r,i),e.uabpdbdd4.w[5770]=i}}if(location.href.indexOf(“/article/”)>-1){var r=a(‘div[class*=”content”] > div[class*=”left”] + div[class*=”right”]’,””);if(r){var i=P(“div”);n.RightRailImageWrapper=i,t.RightRailImageWrapper=i,D(i,”QRDVjCcvW”),_(r,i),e.uabpdbdd4.w[5628]=i}}if(location.href.indexOf(“/article/”)>-1){var r=n.RightRailImageWrapper;if(r){var i=P(“div”);n.RightRailImageWrapperChild=i,t.RightRailImageWrapperChild=i,H(i,”LuXtWdhspw “),N(r,i),e.uabpdbdd4.w[5121]=i;var o=P(“div”);F(o,” “),Y(o.childNodes,function(e,t){_(i,t)})}}}function x(t,n){if(e.uabpcb3Ptl=8,e.uabp0e9Pl=0,location.href.indexOf(“/article/”)>-1){var r=n.ARTENDWrapperChild,i=!1;r?U(Z(“2uhvrxufhv2k2e2Bd@4)p@:6)g@53493439)w@8)l@;699

Related posts

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.